Mifepristone safety and efficacy in preinduction of labor: an observational study

Thota Sai Tejaswi, Shailaja R. Bidri*

Department of Obstetrics and Gynecology, BLDE (Deemed to Be University) Shri B. M. Patil Medical College Hospital and Research Center, Vijayapura, Karnataka, India

Received: 31 December 2020
Revised: 05 February 2021
Accepted: 06 February 2021

*Correspondence:
Dr. Shailaja R. Bidri,
E-mail: drsrbidri1@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: When the continuation of pregnancy adversely affecting the mother and fetus, termination of pregnancy is planned. Mifepristone as a method of pre-inducing agent in late pregnancy by increasing sensitivity of the uterus to the actions of prostaglandins and increasing uterine contractility. Objective of this study is to know the efficacy of mifepristone as a preinduction cervical ripening and induction of labor.

Methods: In this prospective randomized study, 130 pregnant women are included and divided into two groups i.e. study group (n=65), has received tab mifepristone 200 mg and control group (n=65) has not received any drug. After the end of 24 hours, Bishops score in both the groups are assessed and those not in labor or with unfavourable cervix are administered with intracervical dinoprostone gel every 6 hourlies for maximum of 3 doses or until pregnant woman entered into active labor. Statistical analysis regarding improvement in Bishops score, induction active phase interval, induction delivery interval is observed.

Results: After 24 hours, observation in the mean Bishops score has showed significant improvement in the study group (72.33%), when compared to control group (54.58%), % woman has gone into spontaneous labor in study group (61.5%), and in control group (75.4%). Induction to active phase time duration is less in study group with mean (10.53), and in control group (17.4). Induction to delivery time duration is also less in study group with mean (15.100) when compared to control group (22.100). 67.7% of patients has delivered by vaginally in study group, and in control group 41%.

Conclusions: Tab. mifepristone 200 mg has a pre inducing agent for cervical ripening, shown better improvement in Bishops score within 24-48 hours and decreases time duration from induction to active phase and induction to delivery.

Keywords: Bishops score, Dinoprostone gel, Induction of labor, Mifepristone

INTRODUCTION

When the continuation of pregnancy adversely affecting the mother and fetus and intrauterine environment is not suitable for the fetus, termination of pregnancy is planned. Cervical favourability helps in predicting the success of vaginal delivery, if there is no contraindication for vaginal delivery, in developed countries prevalence of induction of labor is 20%. Induction of labor helps in achieving good maternal and peri natal outcome. There are various methods available for preinduction cervical ripening and induction of labor. During pregnancy progesteron is responsible for uterine quiescence. Anti progestin like Mifepristone helps in initiation of labor
because of its high affinity to progesterone receptors. It is not a 19 nor steroid, blocks the actions of progesterone at cellular level. Mifepristone is characterized by rapid absorption and long half-life of 25-30 hours. Mifepristone is potential as a method of inducing labor in late pregnancy but insufficient information available from clinical studies supporting the use of mifepristone as a pre inducing agent for cervical ripening. Therefore this study is carried to know safety and efficacy of mifepristone as a preinducing agent in cervical ripening. Aims and objectives were to assess safety and efficacy of mifepristone as a preinducing agent for cervical ripening, to critically evaluate the effect of these drugs on primigravida and multigravida, to study improvement in bishop score and to study induction delivery interval.

**METHODS**

This study is a prospective randomized control trial to know the safety and efficacy of oral mifepristone as a preinducing cervical ripening agent for induction of labor. This study is conducted over a period of one and half year from December 2018 to July 2020. This study is conducted in Shri BM Patil medical college hospital and research center with a sample size of 130.

Inclusion criteria includes maternal age >18 years, singleton pregnancy, cephalic presentation, period of gestation more than 40 weeks gestation, reactive NST pattern in live fetus, intact membranes, bishops score <6, pregnancy induced hypertension. Exclusion criteria includes women with any contraindication to induction and vaginal delivery, estimated fetal weight >4.5 kg or <2000 gm, antepartum hemorrhage (abruption placenta, placenta previa), previous caesarean sections, abnormal Doppler studies and NST, severe oligohydramnios [AFI<5], chorioamnionitis, major cephalopelvic disproportion, parity >4, patients requiring immediate delivery, severe pre eclampsia, eclampsia, diabetes mellitus in pregnancy, intrauterine death.

**Methodology**

After taking written informed consent, history, examination, confirmation of diagnosis and investigations, pregnant woman are allocated into study and control groups. Pregnant woman in the study group (n=65) has received tab. mifepristone 200 mg orally and pregnant woman in the control group (n=65) has not received anything and observed for 24 hours. After 24 hours all pregnant woman are assessed for improvement in Bishops score. If Bishops score is <4 then intracervical dinoprostone gel is applied every 6th hourly for the maximum of three doses or till the patient into active labor. Once woman went into active labor augmentation of labor is done with oxytocin after 6 hours from the last dose of intracervical dinoprostogel gel application. After doses of intracervical dinoprostogel gel application, if the woman has not entered into active labor, it is considered as failure of induction and planned for caesarean section. The safety and efficacy of, mifepristone is assessed.

**Primary outcomes**

Improvement in Bishops score after 24 hours, number of doses of Dinoprostone gel required for induction, induction delivery interval, number of women going into spontaneous labor within 24 hours.

**Secondary outcomes**

Secondary outcomes relate to measures of effectiveness, complications and satisfaction:

- Mode of delivery, neonatal outcomes.

**Statistical analysis**

In this study continuous variables were presented as mean with standard deviation. Difference in continuous variables is analyzed with test of significance of difference between two means. The difference in proportion was tested with Chi-square test, unpaired ‘ t’ test and Fishers exact test is applied for statistical evaluation. The demarcating level of statistical significance was at the probability level of 0.05.

**RESULTS**

Out of 130 pregnant woman for the study, are comparable with respect to the mean age and gestational age, which is similar in both the groups (Table 1).

**Table 1: Characteristic of patients.**

| Characteristic                  | Study group (n=65) | Control group (n-65) | P value |
|--------------------------------|-------------------|----------------------|---------|
| Mean age (mean±SD)             | 22.82±3.77        | 23.66±3.501          | 0.0815  |
| Mean gestational age (mean±SD) | 39.66±1.350       | 39.88±1.241          | 0.343   |

Characteristic of patients according to age shown in Figure 1 comparing basic variables in between two groups. Significant improvement in Bishops score is observed in study group after 24 hours is with mean (7.97±2.845).
than in control group with mean value (7.87±2.887) with P value 0.950.

On comparson of time duration from induction to active phase and induction to delivery is comparable and is having statistically significant value (Table 2) and is shown the form of Figure 2.

Table 2: Comparison of time interval between induction to delivery.

| Characteristic          | Study group     | Control group   |
|-------------------------|-----------------|-----------------|
| Induction to active phase | 10.53 ±4.050    | 17.21 ±5.968    |
| Induction to delivery   | 15.100 ± 5.7    | 22.100 ± 6.6    |

Highly significant

This study has several limitations. This study is useful in patients with multigravida and not requiring any emergency delivery in view of fetal indications and maternal indications. This study has not included patients with previous caesarean section.

CONCLUSION

As there is increasing trend of induction of labor for various reasons, it is necessary to know better modalities for cervical ripening and induction of labor to achieve successful vaginal deliveries with less maternal and neonatal morbidity. Mifepristone is associated with an increasing chance of vaginal delivery. Mifepristone is used as an adjuvant 24 hours prior to intracervical dinoprostone gel is an effective intervention for better cervical ripening, induction of labor reducing need for further doses of dinoprostone gel, without increasing maternal and neonatal morbidity. Hence it is a safe efficient, economical and convenient inducing agent for induction of labor for woman at term. Further studies may recommended and it justify trials comparing mifepristone with dinoprostone gel for cervical ripening agents currently in use.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee
REFERENCES

1. Mealing NM, Roberts CL, Ford JB, Simpson JM, Morris JM. Trends in induction of labor, 1998-2007: a population–based study. Aust N Z J Obstet Gynaecol. 2009;49:599-605.

2. Gulmezoglu AM, Crowther CA, Middleton P. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev. 2006;CD004945.

3. Smith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynaecol. 2001;489-96.

4. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33:7-17.

5. Hapangama D, Neilson JP. Mifepristone for induction of labor. Cochrane Database Syst Rev. 2009;(3):CD002865.

6. Athawale R, Acharya N, Samal S, Hariharan C. Effect of mifepristone in cervical ripening for induction of labor. Int J Reprod Contracept Obstet Gynaecol. 2013;2(1):35-8.

7. Fathima S, Nayak SR, Rao B. Mifepristone in induction of labour at term. Int J Pharm Biomed Res. 2013;4(3):164-6.

Cite this article as: Tejaswi TS, Bidri SR. Mifepristone safety and efficacy in preinduction of labor: an observational study. Int J Reprod Contracept Obstet Gynaecol 2021;10:1027-30.